Panacea Biotec Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Panacea Biotec hat ein Gesamteigenkapital von ₹8.4B und eine Gesamtverschuldung von ₹206.8M, was einen Verschuldungsgrad von 2.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ₹12.7B bzw. ₹4.3B.

Wichtige Informationen

2.5%

Verhältnis von Schulden zu Eigenkapital

₹209.90m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	₹1.80b
Eigenkapital	₹8.38b
Gesamtverbindlichkeiten	₹4.02b
Gesamtvermögen	₹12.41b

Jüngste Berichte zur Finanzlage

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Jun 05

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Sep 17

Recent updates

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Jun 05

Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

Apr 04

Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Sep 23

Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

Jul 28

How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Feb 14

Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

Jan 06

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Sep 17

If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

Aug 03

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PANACEABIODie kurzfristigen Aktiva des Unternehmens (₹5.4B) übersteigen seine kurzfristigen Passiva (₹3.3B).

Langfristige Verbindlichkeiten: PANACEABIODie kurzfristigen Vermögenswerte des Unternehmens (₹5.4B) übersteigen seine langfristigen Verbindlichkeiten (₹969.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PANACEABIO über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: PANACEABIO Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 186.1% auf 2.5% zurückgegangen.

Schuldendeckung: PANACEABIODer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von PANACEABIO für seine Schulden durch das EBIT gut gedeckt sind.

Panacea Biotec Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Recent updates

Joint MD & Executive Director recently sold ₹1.3m worth of stock

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Full year 2024 earnings released: ₹0.19 loss per share (vs ₹5.43 loss in FY 2023)

Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

New minor risk - Market cap size

Third quarter 2024 earnings released: ₹0.37 loss per share (vs ₹3.16 profit in 3Q 2023)

Panacea Biotec Limited to Report Q3, 2024 Results on Feb 13, 2024

Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany

Second quarter 2024 earnings released: ₹1.35 loss per share (vs ₹2.56 profit in 2Q 2023)

Panacea Biotec Limited to Report Q2, 2024 Results on Nov 10, 2023

New major risk - Share price stability

Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 21%

First quarter 2024 earnings released: EPS: ₹1.79 (vs ₹9.17 loss in 1Q 2023)

Panacea Biotec Limited to Report Q1, 2024 Results on Aug 12, 2023

Full year 2023 earnings released: ₹5.51 loss per share (vs ₹176 profit in FY 2022)

Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹8.03 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.56 (vs ₹8.65 loss in 2Q 2022)

Insufficient new directors

Panacea Biotec Limited Announces Demise of Shri Soshil Kumar Jain, the Founder, Chairman

Panacea Biotec Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: ₹9.17 loss per share (vs ₹9.36 loss in 1Q 2022)

Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022

Panacea Biotec Limited to Report Q1, 2023 Results on Aug 09, 2022

Insufficient new directors

Full year 2022 earnings released: EPS: ₹176 (vs ₹23.88 loss in FY 2021)

Insufficient new directors

Panacea Biotec Limited Appoints Narotam Kumar Juneja as an Additional Director

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

First quarter 2022 earnings released: ₹9.36 loss per share (vs ₹5.41 loss in 1Q 2021)

Panacea Biotec Announces Receipt of Manufacturing License to Produce Sputnik V Vaccine at Baddi, Himachal Pradesh

Full year 2021 earnings released: ₹23.87 loss per share (vs ₹30.67 loss in FY 2020)

The Russian Direct Investment Fund and Panacea Biotec Announce the Launch of Production of the Russian Sputnik V Vaccine Against Coronavirus

New 90-day low: ₹191

How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Third quarter 2021 earnings released: ₹6.54 loss per share (vs ₹3.29 loss in 3Q 2020)

Panacea Biotec Limited to Report Q3, 2021 Results on Feb 12, 2021

Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

New 90-day high: ₹245

Second quarter 2021 earnings released: ₹3.09 loss per share

Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020

New 90-day low: ₹181

Panacea Biotec Limited Announces Resignation of Sunanda Jain and Mr. Sumit Jain, Whole-Time Directors

Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited.

Panacea Biotec Limited Announces Completion of its Phase I/II Study to Evaluate the Safety and Immunogenicity of Vaccine, DengiAll, Single-Dose Live-Attenuated Tetravalent Vaccine

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

First quarter earnings released

First quarter earnings released

Panacea Biotec Limited to Report Q1, 2021 Results on Sep 03, 2020

If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen